Practice Changing Updates on Advanced and Intermediate HCC

Enhancing Survival with Cancer Immunotherapy

The objectives of this Digital Learning Series are to help practitioners and clinicians Enhance survival of their patients with novel cancer immunotherapies Manage toxicities and immune injury.

CME points available for Singaporean practitioners (subject to SMC approval).

Advanced HCC Module

Intro
22 June
5 min
Topic

Welcome and Introductions

Prof. Lim Seng Gee
Video 1
22 June
10 min
Topic

Exploring the rationale for combination
immunotherapy in HCC

Prof. Toh Han Chong
Video 2
29 June
10 min
Topic

Latest Clinical Data for Combination of Immunotherapy and Targeted Therapy in Advanced HCC

Prof. Toh Han Chong
Video 3
6 July
10 min
Topic

Latest Clinical Data for Dual Immunotherapy
in Advanced HCC

Prof. Thomas Yau
Video 4
6 July
15 min
Topic

Molecular Targeted Therapy in Advanced HCC: Is there still a role?

Dr. Chee Cheng Ean
Video 5
13 July
10 min
Topic

Management of toxicities and immune related AEs with systemic therapy in HCC

Prof. Thomas Yau
Video 6
13 July
10 min
Topic

Management of hepatotoxicity with systemic therapy in HCC

Prof. Robert Gish

Patient case studies in the
multi-disciplinary management of Advanced HCC

Tuesday, July 21, 2020
60 min (8-9pm SGT)

July 21, 2020

  • LIVE WEBINAR
  • CASE DISCUSSION
  • ADVANCED HCC MANAGEMENT
Prof. Toh Han Chong

National Cancer Centre, Singapore

Dr. Chee Cheng Ean

National University Cancer Institute, Singapore

Prof. Thomas Yau

The University of Hong Kong, China

Prof. Robert Gish

University of Nevada Schools of Medicine, USA

Prof. Lim Seng Gee

National University Health System, Singapore

Intermediate and Early HCC Module

Video 7
27 July
15 min
Topic

Evolving landscape of loco regional and immunotherapy combination in intermediate HCC

Prof. Pierce Chow
Video 8
3 Aug
15 min
Topic

Transition from loco regional to systemic therapy in intermediate-stage HCC

Dr. Kamarjit Singh Mangat
Video 9
11 Aug
15 min
Topic

Adjuvant and neoadjuvant immunotherapy in
early stage HCC

Prof. Pierce Chow

Patient case studies in the multi-disciplinary management
of Early and Intermediate HCC

Tuesday, Aug 18, 2020
60 min (8-9pm SGT)

Aug 18, 2020

  • LIVE WEBINAR
  • CASE DISCUSSION
  • INTERMEDIATE & EARLY HCC MANAGEMENT
Prof. Lim Seng Gee

National University Health System, Singapore

Prof. Pierce Chow

National Cancer Centre, Singapore

Dr. Kamarjit Singh Mangat

National University Hospital, Singapore

Dr. Chee Cheng Ean

National University Cancer Institute, Singapore

Dr. Mak Lung Yi

University of Hong Kong,
Hong Kong (SAR)

Prof. Toh Han Chong

Dr Toh Han Chong is Senior Consultant and Deputy Director, National Cancer Centre Singapore (NCCS). He is Associate Professor at the Cancer & Stem Cell Biology Program, Duke-NUS, and adjunct Principal Investigator, Singapore Immunology Network and Institute of Molecular and Cell Biology, A*STAR. Dr Toh graduated from the University of London, UK, with an Intercalated Bachelor of Science in ‘Infection and Immunity’ from St Mary’s Hospital Medical School and qualified as a medical doctor from University of Cambridge, United Kingdom.

Dr Toh obtained his Fellowship of the Royal College of Physicians in 2003. He received his medical oncology fellowship training at the Singapore General Hospital, and at the Massachusetts General Hospital, Harvard Medical School, Boston, USA. He then completed a research fellowship in cancer immunotherapy at the Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas, USA.

Dr Toh is alumni of the Harvard Business School. Dr Toh is a recipient of the National Senior Clinician Scientist Award 2017 for translational research in cancer. He received the National Outstanding Clinician Scientist Award 2018. Dr Toh has published over 100 peer-review journal articles. Dr Toh is on the Asia-Pacific Primary Liver Cancer Expert (APPLE) council and is founding chairman of the Singapore Cancer Immunotherapy Consortium. He is on the European Society of Medical Oncology (ESMO) faculty for tumour immunology and immunotherapy.

Prof. Pierce Chow

MBBS, FRCSE, M Med (Surgery), FAMS, PhD

Professor and Course Direcor, Duke-NUS Medical School, Singapore
Senior Consultant, Division of Surgery & Surgical Oncology, National Cancer Center Singapore

Senior Consultant, Department of Hepato-Pancreato-Biliary and Transplant Surgery, Singapore General Hospital

Prof Pierce Chow is senior consultant and Co-Director (Surgical) of the Comprehensive Liver Cancer Clinic at the National Cancer Centre Singapore and Senior Consultant Surgeon in HPB and Transplant Surgery at the Singapore General Hospital. He is concurrently Professor and Course Director at Duke-NUS Medical School Singapore.

Prof Chow leads collaborative multi-disciplinary research on intra-tumoral genomic, immunomic and metabolomic heterogeneity in HCC and their applications to precision medicine. He co-founded the Asia-Pacific Hepatocellular Carcinoma Trials Group in 1997 and has been the protocol chair of 7 prospective multi-national trials. In 2005 he led the multi-disciplinary research that developed BrachySil® (now OncoSil®) and the subsequent first-in-man trial. In 2012 the National Medical Research Council Singapore conferred him the National Outstanding Clinician-Scientist Award for improving clinical outcomes of patients with his research on Liver Cancer.

In 2016 Prof Chow was awarded the NMRC Translational-Clinical Research Grant for the National Flagship Program in Liver Cancer and launched the multi-national PLANET study (Precision Medicine in Liver Cancer Asia-Pacific Network). In 2017 he received additional funding from BMRC to develop the multi-institutional PuRPOSE Program to develop a patient-specific diagnostic and predictive platform to improve treatment of liver cancer.

Dr. Cheng Ean Chee

Dr. Cheng Ean Chee, is a Senior Consultant in Medical Oncology at the National University Cancer Institute, Singapore (NCIS). She is also Assistant Professor of Medicine, Yong Loo Lin School of Medicine, National University of Singapore and Program Director of the Medical Oncology Senior Residency Program, National University Health System, Singapore. She is board certified by the American Board of Internal Medicine (ABIM) in Internal Medicine (Mayo Clinic, USA), Medical Oncology (Mayo Clinic, USA) and Haematology (Mayo Clinic, USA). Dr. Chee treats patients and conducts clinical trials in liver and gastrointestinal (GI) tract cancers. She is also involved in drug development of novel agents and phase I trials.

Dr. Kamarjit Singh Mangat

Dr Kamarjit qualified in 1993, UK, then completed Basic Surgical Training in UK and Australia, obtaining Fellowship of Royal College of Surgeons, London.

Interest in Interventional Radiology led to Radiology training, Fellowship of the Royal College of Radiologists UK and a fellowship in Interventional Radiology. Specialist interest in Hepatobiliary Radiology led to a sabbatical at University of California, San Diego.

From 2005 to 2014 he was a Consultant Radiologist at Queen Elizabeth University Hospital Birmingham, UK working with the Liver Unit (one of the largest in the world), and also Birmingham Children’s Hospital. From 2010 to 2014 he was the Head of Radiology.

In 2014 he was invited to lead liver radiology services at National University Hospital Singapore, and is currently a Senior Consultant Radiologist and Research Director for the Radiology Department.

He has expertise in all forms of liver imaging and intervention, in particular TIPS, post-transplant intervention, biliary procedures, Budd-Chiari syndrome and minimally invasive treatment of tumours using ablation techniques, TACE and SIRT.

Prof. Thomas Yau

MD(HK), MBBS (HK), MRCP (UK), FRCP(London), FHKCP (Med Onc), FHKAM (Medicine)

Clinical Associate Professor in Medical Oncology
University Department of Medicine
Li Ka Shing Faculty of Medicine
The University of Hong Kong

Dr Yau graduated from the University of Hong Kong and started his medical oncology training initially at Queen Mary Hospital, Hong Kong. He was later employed as Specialist Registrar and Clinical Research Fellow at Royal Marsden Hospital, London.  He is currently Associate Professor in Department of Medicine, The University of Hong Kong and Principal Investigator in State Key Laboratory for Liver Disease.

His main research interests are gastrointestinal oncology, early phase clinical trials and translational research. He pioneered Hong Kong Liver Cancer classification and is actively involved in the global drug development in hepatocellular cancer.  He had published more than 120 peer-review publications with articles in various leading oncology journals, namely Lancet, Lancet Oncology, Cell Stem Cell, Gastroenterology, Hepatology and Clinical Cancer Research.  He had also delivered more than 180 invited regional and international lectures.  He currently serves as associate editor and the editorial board members of many international peer-reviewed journals.

He is currently the International Member of US NCI Hepatobiliary Task Force, Vice President of Asia Pacific Neuroendocrine Tumour Society, International Faculty Board Member of International Association of Surgeons Gastroenterologist and Oncologists, General Secretary of Hong Kong Liver Cancer Foundation, and member of many international professional societies.

He is also the council member of Hong Kong Sustainable Council and the advisor of various Hong Kong Government advisory committees.

Prof. Lim Seng Gee

Professor Seng Gee Lim, FRACP, FRCP, FAMS, MD, is Director of Hepatology at the Division of Gastroenterology and Hepatology, National University Health System, Singapore, and was previously Chief of Division. He graduated in 1980 from Monash Medical School completed his research MD at the Royal Free Hospital. He is a member of the editorial boards for Liver International, Journal of Viral Hepatitis, Hepatology International, Alimentary Pharmacology and Therapeutics, Lancet Gastroenterology & Hepatology, and Evidence Based Internal Medicine Solutions, He is also on the advisory board of Gilead Sciences, Novartis Pharmaceuticals, Bristol Myers Pharmaceuticals, Merck Sharpe and Dohme Pharmaceuticals, Springbank, Abbvie and Abbott Diagnostics.

He is currently chairman of the Singapore Hepatology Conference and Science of HBV cure conference, and was previously the Chairman of the Asia Pacific Association for Study of the Liver (APASL) Liver Week 2013 Congress. He served as Governing Council member from 2014-2018 of the International Association for Study of Liver (IASL), and has been appointed to the AASLD Asia Pacific Regional Advisory Council in 2018. He is faculty at the Asia Pacific EBM workshop. His research includes clinical trials of new treatments for chronic hepatitis B and C, and translational research in viral hepatitis, involving molecular biology and immunology of hepatitis B. He has over 207 peer review publications and has been awarded over $36 million in grant funding for his research, including a recent award of a $25 million National Translational Clinical Research grant in 2015 to investigate eradication of HBV. In 2018 he was awarded the NMRC Clinician Scientist Award for research in HBV.

Prof. Robert Gish

Dr Gish was first in Pharmacy School at the University of Kansas and then obtained his medical degree from the University of Kansas Medical School in Kansas City, Kansas. He completed a 3-year internal medicine residency at the University of California, San Diego, and a 4-year gastroenterology and hepatology fellowship at the University of California, Los Angeles which included transplant medicine.

Dr. Gish is a fellow of the American Association for the Study of Liver Disease, the American Society of Transplantation and the American College of Physicians.

He has served on the editorial boards of American Journal of Gastroenterology, Hepatology, Journal of Hepatology, Digestive Diseases and Sciences, and Gastroenterology, among many others. He has co-authored a public health policy for liver health in Vietnam focusing on HBV and is also assisting with the development of viral hepatitis health care policies in Georgia, Armenia, and the Philippines. He was a major early contributor to decipherment methods for the detection of hepatitis B and C virus and characterizing its epidemiology and clinical presentation in humans. He was involved in studies that led to the genotypic classification strategies and methods now in use worldwide. He has published more than 700 original articles, review articles, abstracts, and book chapters.

Robert G. Gish, MD, is currently an Adjunct Professor of Medicine at the University of Nevada Schools of Medicine in Las Vegas and in Reno. He serves as an Adjunct Professor of Pharmacy at Skaggs School of Pharmacy and Pharmaceutical Sciences at UCSD. In addition, he is also Medical Director of the Hepatitis B Foundation in Doylestown, Pennsylvania.

Menu